Background
Introduction
The importance of lipoproteins and haemostasis in the aetiology of atherosclerosis is well established. Perturbation in the balance between coagulation and fibrinolysis can promote the development of atherosclerosis and a number of studies have shown that disturbances in lipoprotein metabolism can influence this balance 1 . Triglycerides and very-low-density lipoprotein (VLDL) elevate Factor VII coagulant activity (FVIIc) and also impair fibrinolysis by increasing plasminogen activator inhibitor 1 (PAI-1) activity 2 . Moreover, both VLDL and oxidized low density lipoprotein (LDL) support the assembly of the prothrombinase complex of phospholipids, calcium ions and coagulation factors V, X and II 3 . In contrast, the antiatherogenic lipoprotein, high density lipoprotein (HDL) has both anti-coagulatory and pro-fibrinolytic properties 4, 5 , perhaps due to an ability to inhibit VLDL-stimulated tissue factor synthesis 2 and activate factor X 6, 7 .
The principal apolipoproteins of LDL and HDL are apolipoprotein B-100 (apo B-100) and apolipoprotein A-I (apo A-I), respectively and it has been suggested that these might provide better indices of atherosclerosis risk than the lipoprotein cholesterol concentrations 8, 9 . The importance of the second most prominent HDL apolipoprotein, apolipoprotein A-II (apo A-II), is less clear, with both pro-and anti-atherogenic properties having been described 10, 11 . In vitro studies suggest that the apolipoproteins may have discrete, mainly anti-coagulatory, interactions with the haemostatic system.
For example, apo A-I and apo A-II can inhibit activation of Factor X by Factor VII and tissue factor 6, 12 and apo A-I inhibits production of the prothrombinase complex by limiting the availability of anionic lipids on extracellular surfaces 13 . Moreover, apoB-100 can inhibit tissue factor activation 14 . However, in vivo approaches to understanding these relationships appear extremely limited.
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The Heart Disease and Diabetes Risk Factors in a Screened Cohort Study (HDDRISC) is an open, occupational cohort study, which has included an unusually detailed range of risk factor measurements. In the present analysis we have investigated relationships between the haemostatic variables fibrinogen, FVIIc and factor X coagulant activity (FXc), the apolipoproteins apo A-I, apo A-II and apoB-100 as well as plasma triglycerides and total, LDL and HDL cholesterol.
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Participants and Methods
Design
The Heart Disease and Diabetes Risk Indicators in a Screened Cohort (HDDRISC)
Study is a cohort study of metabolic risk factors for the development of coronary heart disease and diabetes 15, 16 . The study began in 1971 as a company health program, in the course of which participants received a range of metabolic, clinical and laboratory measurements. The present analysis concerns the 186 Caucasian male recruits who, between 1994 and 1998, had both apolipoproteins and haemostatic factors measured.
Written, informed consent to the study was obtained in each case, and local research ethics committee approval was given.
Procedures
Participants were instructed to have fasted overnight (>12h), to have taken only water and refrained from cigarette smoking on the morning of their test. Height and weight were measured and a clinical history was taken including details of exercise habits, smoking and alcohol consumption. The participants rested for 15 minutes in the semirecumbent position and their systolic and diastolic blood pressure were recorded using a mercury sphygmomanometer. An indwelling cannula was inserted into an antecubital vein in each arm. Blood samples were taken for fasting plasma measurements. All samples were kept on ice before separation of plasma, which took place within 1 hour of the sample being taken. Samples for routine biochemical measurements were stored at 4˚C before analysis. Plasma samples for measurement of haemostatic factors were frozen immediately. 
Laboratory Measurements
Data analysis
For entry in correlation and regression analyses, cigarette smoking was categorized as: never smoked/ex-smokers (0), or less than 5 (1), 5-14 (2), 14-24 (3), or more than 24 (4) cigarettes/day. Alcohol intake was expressed as units consumed per week (a unit of alcohol approximates 10 ml or 8 g pure ethanol and is the amount contained in a half-pint (284 ml) of beer, a single glass (125 ml) of ). All participants were free of diabetes (maximum fasting plasma glucose 6.1 mmol/l) and cardiovascular disease. Eighty-six percent of participants (n=159) had never smoked or were ex-smokers at the time of testing. Eighty-two percent of participants took no alcohol or described themselves as light irregular drinkers. Eighteen percent drank regularly up to 28 U/wk and only a single individual drank more than 28 U/wk. Forty-four percent of participants did not exercise at all whereas 41% were engaged in moderate exercise and 16% took aerobic exercise. Two individuals were taking lipid-lowering agents (both statins), 11
were taking blood pressure-lowering agents and 3 uric-acid lowering agents. Two individuals reported regular aspirin use. Median and interquartile ranges for study variables are shown in Table 1 .
The strongest univariate correlate of fibrinogen ( In multiple linear regression analysis, with age, BMI, alcohol intake, exercise habit and current smoking included as predictor variables (Table 3) The present study is, to the best of our knowledge, the first in humans in vivo to examine specifically relationships between haemostatic factors and a range of the principal apolipoproteins that includes apo A-II. We found positive associations between apo B and apo A-II and FVIIc and FXc, but only the associations with apo A-II were fully independent. It was also noteworthy that total cholesterol and triglycerides were independently associated with FVIIc and FXc and that fibrinogen showed no associations with variables related to lipid metabolism. These findings were made in a group of apparently healthy Caucasian males, free of diabetes and cardiovascular disease and at relatively low risk of developing these conditions. Whether they are equally present in women, other ethnic groups or in at-risk or disease states remains to be established.
Our principal novel finding is the independent, positive in vivo association between apo A-II and FVIIc and FXc. For FXc, this contrasts with the relationship that would expected on the basis of the in vitro demonstration that apo A-II can inhibit factor X activation 6, 12 . Nevertheless, there are several potential explanations for the positive relationship we observed. For example, a specific property of apo A-II that could affect FVIIc and FXc is its ability to displace the antioxidant enzyme paraoxonase from HDL particles 23 and render them proinflammatory 24 . Paraoxonase protects LDL from lipid peroxidation 25 and increased LDL oxidation can reduce the activity of LDL-bound tissue factor pathway inhibitor 14, 26 . This would be expected to increase the activation Activation of factor VII by VLDL appears to be mediated by increased availability of phospholipids 36 and this also appears to be important in the activation of factor X
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Apo A-II can directly stimulate ATP binding cassette transporter 1 (ABCA1)-mediated efflux of phospholipids and free cholesterol 42 , which could contribute to activation of factors VII and X and the positive association we observed between apo A-II and FVIIc and FXc. Another possible connection might be the ability of peroxisome proliferatoractivated receptor-α to upregulate both ABCA1 expression 43 and apo A-II gene transcription 44 . However, these potential mechanisms derive from animal studies and apply equally to apo A-I and we found no relationship between apo A-I and FVIIc and FXc. Although traces of apo-AII may be synthesised in the intestine, the majority appears to be synthesised in the liver 45 . Hepatic metabolism could play a role in the associations we observed and, in contrast to previous studies 46 , a positive relationship between liver steatosis and apo A-II has now been reported in patients with chronic hepatitis C 47 . However, liver disease tends to be associated with low levels of activated factor VII
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As yet, therefore, there is no definitive mechanism linking apo A-II levels with FVIIc and FXc although there remains the possibility that, rather than apo A-II affecting FVIIc and FXc, these coagulation factors are affecting apo A-II levels. Genetic polymorphisms were not evaluated in our study. Nevertheless, this possibility could be explored in further studies in relation to genetic variation at residue 353 of factor VII which, in the Arg353 variant, is associated with both higher factor VII antigen levels and higher FVIIc 49 . Investigation of this possibility would be complex, however, given the marked interaction between factor VII genotype and triglyceride concentrations 49 and the associations mentioned above between triglyceride metabolism and apo A-II.
It is important to note that our novel findings with regard to apo A-II are supported by our confirmation of other associations previously reported by others. These include the positive associations of FVIIc and FXc with total cholesterol and triglycerides 50, 51 but not with LDL or HDL 2, 52 . Also in agreement with our findings with regard to fibrinogen some previous studies found no significant associations between fibrinogen and serum lipids and lipoproteins 2, 53 . However, in large population studies, fibrinogen has been weakly and positively associated with total and LDL cholesterol, and weakly and negatively associated with HDL cholesterol [54] [55] [56] . It is possible that similarly weak associations are present in the cohort we studied, but larger numbers would have been needed to demonstrate them as significant.
In contrast to the negative association expected from in vitro studies 
